Cannabidivarin or CBDV is a non-psychoactive cannabinoid similar to cannabidiol (CBD) in structure.

Recent research is showing the medical potential of CBDV to treat epilepsy and other neurological conditions. With human testing yet to come, this cannabinoid has shown to be an effective anticonvulsant and antiepileptic in mice studies.

CBDV have demonstrated anticonvulsant activity in animal and human models and are demonstrating promising clinical trial results.

CBDV is most common amongst landrace Indica strains. Landrace strains are the genetically pure cannabis strains that grow in the wild. They are not cross-contaminated by other breeds. These strains aren’t influenced by human experimentation.

CBDV is more present in low-THC and high-CBD strains like Harlequin (Hybrid), Critical Mass, Shark Shock (Indica), Critical Mass (Indica), Mandarin Kush (Hybrid), Island Sweet Skunk (Sativa), and Boston OG (Hybrid).

In October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome and in February 2018 for treatment of Fragile X Syndrome.

Orphan drug designations encourage companies to develop drugs in rare diseases by providing various financial incentives.

Cannabidivarin (CBDV) Side Note:

In 2015 the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application Serial Number 13/075,873, a patent application which covers the use of cannabidivarin (CBDV) for treating epilepsy to GW Pharmaceuticals.

GW Pharmaceuticals was approved by the US to release Epidiolex (a prescription version of Cannabidiol). Epidiolex is the first prescription pharmaceutical formulation of highly purified CBD released in the U.S. for seizures associated with LGS or Dravet syndrome.

GW Pharmaceuticals will be presenting data from their Phase 3 trials of Epidiolex at the American Academy of Neurology (AAN) Annual Meeting, May 4-10, 2019, in Philadelphia.

Leave a Reply

Your email address will not be published. Required fields are marked *